Wedbush raised the firm’s price target on Protagonist Therapeutics (PTGX) to $70 from $58 and keeps an Outperform rating on the shares.Optimize ...

Truist raised the firm’s price target on Protagonist Therapeutics (PTGX) to $76 from $60 and keeps a Buy rating on the shares. The firm cites ...

The joint development project of Protagonist Therapeutics and Johnson & Johnson (NYSE:JNJ) produced Icotrokinra as their ...

Results from the phase 3 ICONIC-LEAD study presented at this year’s American Academy of Dermatology (AAD) annual meeting ...

The market slump continued yesterday as President Donald Trump's "period of transition" fuels stagflation fears. It led to ...

We recently compiled a list of the 10 Firms Buck Market Bloodbath on Monday. In this article, we are going to take a look at ...

HC Wainwright reissued their buy rating on shares of Protagonist Therapeutics (NASDAQ:PTGX – Free Report) in a research note ...

Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Free Report) has been assigned an average recommendation of “Buy” from the nine research firms that are presently covering the stock, Ratings reports.

On Monday, Protagonist Therapeutics, Inc. PTGX announced topline results from ANTHEM-UC Phase 2b study of icotrokinra ...

Protagonist Therapeutics shares were up 28% to $49.25 after the company reported positive topline results from a Phase 2b study of icotrokinra, conducted by partner Johnson & Johnson.

Johnson & Johnson’s once-daily oral peptide has bested Bristol Myers Squibb’s reigning oral psoriasis med Sotyktu in a ...

We have the answer for Protagonist of the Metroid video-game series crossword clue that will help you solve the crossword puzzle you're working on!